RxDoctor Payments Data

Shashi Raja, MD

Hospitalist · Morristown, NJNPI 1639102627

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 24.8% of the total. Reporting peaked in 2019 at $417 and has fallen 72.2% since, to $116 in 2025. Among hospitalist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,371in general payments, 2019–2025

Across 84 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$339
  • Pfizer$310
  • Merck$243
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$185
  • E.r. Squibb & Sons, L.L.C.$128
  • Avanir Pharmaceuticals, Inc.$41
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$1,371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,371 in reported general payments places this provider in the 90th percentile of 567 hospitalist providers in New Jersey.

See all hospitalist providers in New Jersey

Medicare billing

Part B allowed, 2024
$208,750
Medicare patients
615
Services billed
1,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$19,960
Torsemide63$598
Metoprolol Succinate50$442
Pantoprazole Sodium55$287
Nitroglycerin13$269
Fluticasone Propionate12$268
Atorvastatin Calcium35$255
Valsartan26$234
CefuroximeCefuroxime Axetil24$217
Spironolactone36$173
Tamsulosin Hcl19$169
ClopidogrelClopidogrel Bisulfate18$153
Prednisone26$150
Potassium Chloride16$133
Amiodarone Hcl16$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$310$19,96026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 hospitalist providers in New Jersey.

Other hospitalist in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →